Dr. Sinha has served as Chief Scientific Officer (CSO) of BridgeBio Pharma and Eidos Therapeutics since 2016. At Eidos, she leads non-clinical research, DMPK and CMC teams to support the development of AG10 in transthyretin amyloidosis. Previously, Dr Sinha served as the CSO of Global Blood Therapeutics and held senior research positions at Portola Pharmaceuticals, Millennium Pharmaceuticals, and COR Therapeutics, Inc. She has extensive experience in discovery and preclinical development of agents involved in treatment of hematologic, cardiovascular and inflammatory diseases, including Oxbryta (voxelotor), Bevyxxa (betrixaban), and Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B Sc. with honors in chemistry from Presidency College.
AG10, An Investigational Therapeutic for Cardiac Amyloidosis
AG10 is an investigational small molecule designed to potently stabilize tetrameric transthyretin (TTR). AG10 binding was designed to mimic a variant TTR, T119M, considered a rescue mutation because co-inheritance has been shown to prevent or ameliorate TTR amy-loidosis in individuals also inheriting a pathogenic variant.